Merkel Cell Carcinoma: Staging and Treatment
What is staging for cancer?
Staging is the process of learning how much cancer is in your body and where it is. Tests like biopsies, CTs, and MRIs are done to help stage your cancer. Your providers need to know about your cancer and your health so that they can plan the best treatment for you.
Staging looks at the size of the tumor and where it is, and if it has spread to other organs. The staging system for Merkel cell carcinoma is called the “TNM system,” as described by the American Joint Committee on Cancer. It has three parts:
- T-describes the size/location/extent of the tumor.
- N-describes if the cancer has spread to the lymph nodes.
- M-describes if the cancer has spread to other organs (metastases).
Your healthcare provider will use the results of the tests you had to determine your TNM result and combine these to get a stage from 0 to IV.
How is Merkel cell carcinoma (MCC) staged?
MCC is staged using the TNM system. The most common staging system used for MCC is the pathological stage. The pathological stage is decided when tissue removed during surgery is tested. If surgery has not been done, a clinical stage can be given using results from a physical exam, biopsy, and imaging tests. Staging will help determine the best treatment options.
The staging system is very complex. Below is a summary of the pathological staging system. Talk to your provider about the stage of your cancer.
- Stage 0 (Tis, N0, M0): The cancer is only in the outermost layer of skin called the epidermis. It has not spread to the lymph nodes or other parts of the body. It is also called carcinoma in situ (Tis).
- Stage I (T1, N0, M0): The cancer is no more than 2cm across and has not spread to nearby lymph nodes or distant sites.
- Stage IIA (T2 or T3, N0, M0): The cancer is between 2 and 5cm across or more than 5cm across and has not spread to lymph nodes or other parts of the body.
- Stage IIB (T4, N0, M0): The cancer has grown into nearby muscle, bone, or cartilage but has not spread to nearby lymph nodes or distant parts of the body.
- Stage IIIA (T1/T2/T3/T4, N1a(sn)/N1a, M0): The cancer is any size and may have grown into nearby tissues. It has also spread to nearby lymph nodes found during a lymph node biopsy or surgery and was not seen on exams or imaging tests. It has not spread to distant parts of the body.
- Stage IIIA (T0, N1b, M0): There is no sign of primary cancer and it has spread to nearby lymph nodes that were seen on exam or imaging tests and confirmed by biopsy or surgery. It has not spread to distant sites.
- Stage IIIB (T1/T2/T3/T4, N1b/N2/N3, M0): The cancer is any size and may have grown into nearby tissues. It has not spread to distant sites. It also must meet any of these criteria:
- Spread to nearby lymph nodes (seen on exams or imaging tests and confirmed with a biopsy or surgery).
- Spread toward nearby lymph node areas without reaching the lymph nodes.
- Spread toward a nearby lymph node area and has reached the nodes.
- Stage IV (T0/T1/T2/T3/T4, Any N, M1): The cancer is any size and may have grown into nearby tissues. It may or may not be in the nearby lymph nodes. It has spread to distant lymph nodes or organs.
How is MCC treated?
Treatment for MCC depends on things like your cancer stage, age, overall health, and testing results. Your treatment may include some or all of the following:
Surgery is the main treatment for MCC. It can be done to diagnose MCC and to see if it has spread. Often, a skin biopsy is done before your provider thinks you have MCC. A small part of the lesion is removed and tested to see what kind of cells it is made of. A sentinel lymph node biopsy will likely be done to help determine the stage of your cancer. Once your diagnosis is confirmed, surgery to remove the cancer will be done, often a wide local excision that removes the cancer and some extra tissue around the cancer.
If cancer is found in your lymph nodes, a lymph node dissection will be done, which removes other nearby lymph nodes. In some cases, a MOHS procedure is done to remove the lesion. The amount of tissue that needs to be removed may be large, and you might not have enough healthy tissue to heal. In these cases, you may need skin grafts and reconstructive surgery. Your surgeon will talk to you about your options for surgery.
Chemotherapy is the use of anti-cancer medicines that go through your whole body. It is most likely helpful for MCC that has spread to other parts of the body. MCC is rare so it is hard to know which medications work best. The most common chemotherapies used for MCC that has spread are cisplatin, carboplatin, etoposide, and topotecan. Your medical oncologist will talk to you about which chemotherapy regimen is best for you.
You may need radiation therapy. Radiation therapy uses high-energy x-rays to kill cancer cells and it tends to work well for MCC, although there is question about when during treatment it's best to receive radiation. Times when radiation can be used are:
- To treat the area after surgery to kill any leftover cancer cells.
- To treat the cancer if surgery is not an option.
- To treat the lymph nodes near the main tumor.
- Treatment of MCC that has recurred (come back) after surgery.
- To treat MCC that has spread to other parts of the body (metastasis).
Radiation is given 5 days a week over several weeks. Your radiation oncologist will talk with you about the best course of treatment for your cancer.
Immunotherapy is the use of medications that stimulate (rev up) the immune system to attack and kill cancer cells. Avelumab blocks PD-L1, a protein that is found on some MCC cells. Pembrolizumab and nivolumab block PD-1, another protein found on some MCC cells. These medications are given intravenously (IV, into a vein) and can shrink the cancer or slow down its growth.
You may be offered a clinical trial as part of your treatment plan. To find out more about current clinical trials, visit the OncoLink Clinical Trials Matching Service.
Making Treatment Decisions
Your care team will make sure you are included in choosing your treatment plan. This can be overwhelming as you may be given a few options to choose from. It feels like an emergency, but you can take a few weeks to meet with different providers and think about your options and what is best for you. This is a personal decision. Friends and family can help you talk through the options and the pros and cons of each, but they cannot make the decision for you. You need to be comfortable with your decision – this will help you move on to the next steps. If you ever have any questions or concerns, be sure to call your team.
You can learn more about MCC at OncoLink.org.
NCCN Guidelines, Merkel Cell Carcinoma https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf
Amaral, T., Leiter, U., & Garbe, C. (2017). Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. Reviews in Endocrine and Metabolic Disorders, 1-16.
Flohil, S. C., Lee, C. B., Beisenherz, J., Mureau, M. A. M., Overbeek, L. I. H., Nijsten, T., & Bos, R. R. (2017). Mohs micrographic surgery of rare cutaneous tumours. Journal of the European Academy of Dermatology and Venereology, 31(8), 1285-1288.
Galluzzi, L., & Kroemer, G. (2017). Novel immune checkpoint blocker to treat Merkel cell carcinoma. Oncoimmunology, 6(6), e1315496.
Mattavelli, I., Patuzzo, R., Torri, V., Gallino, G., Maurichi, A., Lamera, M., ... & Moglia, D. (2017). Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy. European Journal of Surgical Oncology, 43(8), 1536-1541.
Moshiri, A. S., Doumani, R., Yelistratova, L., Blom, A., Lachance, K., Shinohara, M. M., ... & Asgari, M. M. (2017). Polyomavirus-negative merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. Journal of Investigative Dermatology, 137(4), 819-827.
Paulson, K. G., Lewis, C. W., Redman, M. W., Simonson, W. T., Lisberg, A., Ritter, D., ... & Iyer, J. (2017). Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study. Cancer, 123(8), 1464-1474.
Paulson, K. G., Park, S. Y., Vandeven, N. A., Lachance, K., Thomas, H., Chapuis, A. G., ... & Nghiem, P. (2017). Merkel Cell Carcinoma: Current United States Incidence and Projected Increases based on Changing Demographics. Journal of the American Academy of Dermatology.
Poulsen, M. (2018). Radiation Therapy Rather Than Surgery for Merkel Cell Carcinoma: The Advantages of Radiation Therapy. International Journal of Radiation Oncology* Biology* Physics, 100(1), 14-15.
Spurgeon, M. E., & Lambert, P. F. (2013). Merkel Cell Polyomavirus: A Newly Discovered Human Virus with Oncogenic Potential. Virology, 435(1), 118–130. http://doi.org/10.1016/j.virol.2012.09.029
Tsai, S., & Bordeaux, J. S. (2018). Merkel Cell Carcinoma. In A Practical Guide to Skin Cancer (pp. 143-153).
Springer, Cham.Winkler, J. K., Bender, C., Kratochwil, C., Enk, A., & Hassel, J. C. (2017). PD‐1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma. British Journal of Dermatology, 176(1), 216-219.